Company / Return on Assets (ROA)
Amylyx Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-43.5%
FY2025
5-year range
-155.8% / 9.5%
FY2021-FY2025
Trend
+72.1%
vs FY2024
Sector context
#166 of 213
Health Care
What the data says
Amylyx Pharmaceuticals, Inc.'s return on assets (roa) of -43.5% is lower than 78% of companies in the Health Care sector (FY2025). Declined from 9.5% to -43.5% over the past 2 years.
Based on SEC 10-K filings.
-43.5% in FY2025 with a 3-year CAGR of +7.2%.
Declined from 9.5% to -43.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +7.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company -43.5% Sector average -24.1%
▼
-80.2% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 72.1% year-over-year.
- Currently 19.4pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2023.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -43.5% | +72.1% |
| FY2024 | -155.8% | -1736.9% |
| FY2023 | 9.5% | +118.8% |
| FY2022 | -50.7% | +39.1% |
| FY2021 | -83.3% | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026